Laura L Ekblad1,2, Juha O Rinne3,4, Pauli J Puukka5, Hanna K Laine6,7, Satu E Ahtiluoto8, Raimo O Sulkava8, Matti H Viitanen6,9, Antti M Jula5. 1. Turku PET Centre, University of Turku and Turku University Hospital, P.O. Box 52, 20521, Turku, Finland. llekbl@utu.fi. 2. Turku Health Care Centre, Turku, Finland. llekbl@utu.fi. 3. Turku PET Centre, University of Turku and Turku University Hospital, P.O. Box 52, 20521, Turku, Finland. 4. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland. 5. National Institute for Health and Welfare (THL), Turku, Finland. 6. Turku City Hospital, University of Turku, Turku, Finland. 7. Department of Medicine, University of Turku, Turku, Finland. 8. University of Eastern Finland, Kuopio, Finland. 9. Clinical Geriatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
Abstract
AIMS/HYPOTHESIS: Type 2 diabetes is an independent risk factor for cognitive decline. Insulin resistance occurring during midlife may increase the risk of cognitive decline later in life. We hypothesised that insulin resistance is associated with poorer cognitive performance and that sex and APOE*E4 might modulate this association. METHODS: The association of insulin resistance and APOE*E4 genotype on cognitive function was evaluated in a nationwide Finnish population-based study (n = 5,935, mean age 52.5 years, range 30-97 years). HOMA-IR was used to measure insulin resistance. Cognitive function was tested by word-list learning, word-list delayed-recall, categorical verbal fluency and simple and visual-choice reaction-time tests. Linear regression analysis was used to determine the association between HOMA-IR and the results of the cognitive tests. RESULTS: Higher HOMA-IR was associated with poorer verbal fluency in women (p < 0.0001) but not in men (p = 0.56). Higher HOMA-IR was also associated with poorer verbal fluency in APOE*E4 -negative individuals (p = 0.0003), but not in APOE*E4 carriers (p = 0.28). Furthermore, higher HOMA-IR was associated with a slower simple reaction time in the whole study group (p = 0.02). CONCLUSIONS/ INTERPRETATION: To our knowledge, this is the first comprehensive, population-based study, including both young and middle-aged adults, to report that female sex impacts the association of HOMA-IR with verbal fluency. Our study was cross-sectional, so causal effects of HOMA-IR on cognition could not be evaluated. However, our results suggest that HOMA-IR could be an early marker for an increased risk of cognitive decline in women.
AIMS/HYPOTHESIS: Type 2 diabetes is an independent risk factor for cognitive decline. Insulin resistance occurring during midlife may increase the risk of cognitive decline later in life. We hypothesised that insulin resistance is associated with poorer cognitive performance and that sex and APOE*E4 might modulate this association. METHODS: The association of insulin resistance and APOE*E4 genotype on cognitive function was evaluated in a nationwide Finnish population-based study (n = 5,935, mean age 52.5 years, range 30-97 years). HOMA-IR was used to measure insulin resistance. Cognitive function was tested by word-list learning, word-list delayed-recall, categorical verbal fluency and simple and visual-choice reaction-time tests. Linear regression analysis was used to determine the association between HOMA-IR and the results of the cognitive tests. RESULTS: Higher HOMA-IR was associated with poorer verbal fluency in women (p < 0.0001) but not in men (p = 0.56). Higher HOMA-IR was also associated with poorer verbal fluency in APOE*E4 -negative individuals (p = 0.0003), but not in APOE*E4 carriers (p = 0.28). Furthermore, higher HOMA-IR was associated with a slower simple reaction time in the whole study group (p = 0.02). CONCLUSIONS/ INTERPRETATION: To our knowledge, this is the first comprehensive, population-based study, including both young and middle-aged adults, to report that female sex impacts the association of HOMA-IR with verbal fluency. Our study was cross-sectional, so causal effects of HOMA-IR on cognition could not be evaluated. However, our results suggest that HOMA-IR could be an early marker for an increased risk of cognitive decline in women.
Authors: Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad Journal: Lancet Date: 2006-04-15 Impact factor: 79.321
Authors: Christian Benedict; Manfred Hallschmid; Astrid Hatke; Bernd Schultes; Horst L Fehm; Jan Born; Werner Kern Journal: Psychoneuroendocrinology Date: 2004-11 Impact factor: 4.905
Authors: Gail A Laughlin; Linda K McEvoy; Denise von Mühlen; Lori B Daniels; Donna Kritz-Silverstein; Jaclyn Bergstrom; Kevin Cummins; Claudia Der-Martirosian; Simerjot K Jassal; Elizabeth Barrett-Connor Journal: Psychosom Med Date: 2011-09-23 Impact factor: 4.312
Authors: Otto Tschritter; Hubert Preissl; Anita M Hennige; Michael Stumvoll; Katarina Porubska; Rebekka Frost; Hannah Marx; Benjamin Klösel; Werner Lutzenberger; Niels Birbaumer; Hans-Ulrich Häring; Andreas Fritsche Journal: Proc Natl Acad Sci U S A Date: 2006-07-28 Impact factor: 11.205
Authors: Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold Journal: J Clin Invest Date: 2012-04 Impact factor: 14.808
Authors: Erkki Kronholm; Mikael Sallinen; Pertti Era; Timo Suutama; Raimo Sulkava; Timo Partonen Journal: J Sleep Res Date: 2010-12-06 Impact factor: 3.981
Authors: Sophia Frangou; Masoud Shirali; Mark J Adams; David M Howard; Jude Gibson; Lynsey S Hall; Blair H Smith; Sandosh Padmanabhan; Alison D Murray; David J Porteous; Chris S Haley; Ian J Deary; Toni-Kim Clarke; Andrew M McIntosh Journal: Exp Neurol Date: 2019-04-06 Impact factor: 5.330
Authors: Stefan L C Geijselaers; Pauline Aalten; Inez H G B Ramakers; Peter Paul De Deyn; Annemieke C Heijboer; Huiberdina L Koek; Marcel G M OldeRikkert; Janne M Papma; Fransje E Reesink; Lieke L Smits; Coen D A Stehouwer; Charlotte E Teunissen; Frans R J Verhey; Wiesje M van der Flier; Geert Jan Biessels Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Simon M Laws; Scott Gaskin; Amy Woodfield; Velandai Srikanth; David Bruce; Paul E Fraser; Tenielle Porter; Philip Newsholme; Nadeeja Wijesekara; Samantha Burnham; Vincent Doré; Qiao-Xin Li; Paul Maruff; Colin L Masters; Stephanie Rainey-Smith; Christopher C Rowe; Olivier Salvado; Victor L Villemagne; Ralph N Martins; Giuseppe Verdile Journal: Sci Rep Date: 2017-08-29 Impact factor: 4.379
Authors: Timothy M Hughes; Suzanne Craft; Laura D Baker; Mark A Espeland; Stephen R Rapp; Kaycee M Sink; Alain G Bertoni; Gregory L Burke; Rebecca F Gottesman; Erin D Michos; José A Luchsinger; Annette L Fitzpatrick; Kathleen M Hayden Journal: Alzheimers Dement (Amst) Date: 2017-03-31